Lung Transplant Rejection Clinical Trial
Official title:
The Role of Immune Checkpoints in Lung Transplant: the Pathways of Rejection and the Immunomodulatory Therapeutic Perspectives
The goal of this observational study is to learn about rejection in lung transplantation. The main question it aims to answer is: • what is the role of immune checkpoints in lung transplantation? Participants will describe pathways of rejection in lung transplantation analyzing the immune checkpoints on explanted lungs as well as trans-bronchial biopsies.
Lung transplantation is the less common solid organ transplant performed; it is the treatment of choice for end stage lung disease. Lung transplantation is "problematic" for a number of reasons: low graft availability, high waitlist mortality and unsatisfactory survival. Acute rejection, occurring days to months after surgery, has been identified as one of the main risk factors for the development of chronic rejection: in the first five years after lung transplantation, chronic rejection is the major cause of graft failure, morbidity and mortality. A deep knowledge of the immunological scenarios associated with lung graft tolerance could allow selectively switch-off T-cells involved in the rejection process. The researches, preliminary demonstrated the central role of immunological checkpoints in the development of acute rejection and its evolution towards chronic rejection. The aim of this study is the identification of markers that could be associated with the establishment of lung graft tolerance. The project is articulated into two parts: a retrospective and a prospective section. The retrospective section is constituted by a cross-sectional study of immune checkpoints on lungs explanted during lung re-transplantation for chronic rejection (cohort 1). In addition, the retrospective section includes a retrospective cohort study of immune checkpoints on specimens from transbronchial lung biopsies of participants who received lung transplantation and have 3 years of follow-up (cohort 2). The prospective section is a cohort study of immune checkpoints on specimens from transbronchial lung biopsies and gene expression analysis on immune cells purified from bronchoalveolar lavage; participants will be subjects receiving the lung transplantation during the first year of recruitment and followed for one year (cohort 3). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT06309628 -
Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
|
||
| Withdrawn |
NCT02893176 -
Macitentan in the Treatment of Organ Rejection After Lung Transplantation
|
Phase 4 | |
| Completed |
NCT02441413 -
Transplant Optimization Using Functional Imaging (TROFI)
|
N/A | |
| Recruiting |
NCT05375149 -
Exhaled Breath Particles in Lung Transplantation
|
||
| Active, not recruiting |
NCT03967340 -
PREdiction of Chronic LUng Allograft Dysfunction
|
||
| Active, not recruiting |
NCT05260372 -
Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
|
||
| Recruiting |
NCT06082037 -
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
|
Phase 3 | |
| Recruiting |
NCT04714801 -
Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05170425 -
LAMBDA 002 (Lung Registry) Study
|
||
| Completed |
NCT02474927 -
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
|
Phase 2 | |
| Recruiting |
NCT05006742 -
Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients
|
N/A | |
| Recruiting |
NCT02812290 -
Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
|
||
| Not yet recruiting |
NCT03500575 -
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
|
N/A | |
| Withdrawn |
NCT03805178 -
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
|
Phase 2 | |
| Completed |
NCT03359863 -
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
|
Phase 2 | |
| Active, not recruiting |
NCT03656926 -
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)
|
Phase 3 | |
| Completed |
NCT01985412 -
Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
|
||
| Completed |
NCT04234919 -
Longitudinal Study of Cell Free DNA in Lung Transplant
|
||
| Recruiting |
NCT04837339 -
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
|
N/A | |
| Recruiting |
NCT03090581 -
Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.
|
N/A |